



COMPARISON
OF THE
WHO ATC CLASSIFICATION
&
***Eph*MRA/PBIRG ANATOMICAL**
CLASSIFICATION:

VERSION January 2013

Comparison of the WHO ATC Classification and *EphMRA* / PBIRG Anatomical Classification

The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. *EphMRA* and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence.

In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified.

WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product).

EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only.

The purposes of classification are also different:

The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring.

This classification is recommended by the WHO for use in international drug utilisation research.

The *EphMRA*/PBIRG classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems.

The aim of harmonisation is to reach a “full” agreement of all mono substances in a given class as listed in the WHO ATC Index, mainly at third level: whenever this is not possible, or harmonisation of third level

is too difficult or makes no sense (e.g. C2, R3), the second level will be taken as the reference class.

Harmonisation is not a simple adaptation of two systems; harmonisation is clearly an improvement of the existing systems.

In view of the increasing use of the WHO classification by national and international authorities and institutions with different objectives, it is opportune to have a harmonised classification.

The main benefit is that all parties involved in a given topic, use the same definitions, same substances, and therefore the discussions are easier.

In line with the harmonisation procedure of WHO/EphMRA, this booklet has been prepared to facilitate cross-comparison. The comparison has been based on the WHO guidelines. Whenever possible, we have checked all molecules included in the current WHO/ATC Index with the EphMRA coding.

We have tried to simplify the document and for this reason and according to the pre-agreed mandate of harmonisation, only the 3rd level has been used as a point of reference.

However, in some cases (e.g. A2B1 antiulcer and group L) we have also mentioned the 4th levels in our comparison.

Where the two groups are similar, on the *EphMRA* side only the code and the title has been added.

Where a difference exists, this has been notified using the following symbols:

- ❖ This class/code does not exist (e.g. A03B)
- ➡ The heading or the content of this class may be different (e.g. N5C).
- These substances are classified in a different class.
- + This class is covered by more than one *EphMRA*/PBIRG class

A lot of discrepancies concern rather obsolete products for which there is no need for harmonisation (e.g. products withdrawn from the market, sales of minor importance).

We hope this booklet will improve both the use and understanding of the two systems, in particular for those companies in which the two systems are used by different departments (medical and marketing).

The Committee has tried to make a comprehensive comparison of both systems, but cannot guarantee a 100% level of accuracy.

For complete guidelines on the WHO ATC systems refer to “Guidelines for ATC classification” and for the *Eph*MRA/PBIRG Anatomical classification system refer to “*Eph*MRA / PBIRG classification”.

To obtain the guidelines please contact:

Norwegian Institute of Public Health WHO Collaborating Centre for Drug Statistics Methodology P.O. Box 4404 Nydalen N-0403 OSLO Fax: +47-23408146 email: whocc@fhi.no web: www.whocc.no	Bernadette Rogers Secretary of EPhMRA Minden House 351 Mottram Road Stalybridge, SK15 2SS Cheshire, UK Fax: +44 161 304 8104 Email: MrsBRogers@aol.com	Carol Reilly Executive Director, PBIRG 1758 Allentown Road, Box 209 Lansdale, PA 19446 USA Telephone: [1] 215 855 5255 Fax: [1] 215 855 5622 Email: creilly@pbirg.com .
---	---	--

WHO (Substance based)

EphMRA (Product based)

A ALIMENTARY TRACT AND METABOLISM

A01 STOMATOLOGICAL PREPARATIONS

A01A STOMATOLOGICAL PREPARATIONS

- Preparations for the treatment of **throat** infections (lozenges for common cold conditions) are classified in **R02** - Throat preparations.
- Cevimeline is classified in N7A.



A02 DRUGS FOR ACID RELATED DISORDERS

A02A ANTACIDS

- Plain antiflatulents, see A02BX

A02B DRUGS FOR PEPTIC ULCER and GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

A02B A H2-receptor antagonists

A02B B Prostaglandins

A02B C Proton pump inhibitors

A02B D Combinations for eradication of Helicobacter pylori

A02B X Other drugs for peptic ulcer and gastro-oesophageal disease (GORD)

- Chlorbenzoxamine is classified in A03A.

A ALIMENTARY TRACT AND METABOLISM

A1 STOMATOLOGICALS, MOUTH PREPARATIONS, MEDICINAL DENTIFRICES ETC.

A1A STOMATOLOGICALS

- Products indicated for both the **posterior part of the mouth and throat** infections are classified in **R2A or A1A depending on their main indication.**
- +
- Cevimeline is classified here.

A1B MOUTH ANTIFUNGALS

A2 ANTACIDS, ANTIFLATULENTS AND ANTI-ULCERANTS

A2A ANTACIDS, ANTIFLATULENTS, CARMINATIVES

- Plain antiflatulents are classified in this group.

A2B ANTIULCERANTS

A2B1 H2 antagonists

A2B3 Prostaglandin antiulcerants

A2B2 Acid pump inhibitors

A2B4 Bismuth antiulcerants

+

A2B9 All other antiulcerants

WHO (Substance based)

EphMRA (Product based)

➤ Chlorbenzoxamine is classified here.

A02X OTHER DRUGS FOR ACID RELATED DISORDERS

A2C OTHER STOMACH DISORDER PREPARATIONS

A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

A3 FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS

A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

A3A PLAIN ANTISPASMODICS AND ANTICHOLINERGICS

➤ Chlorbenzoxamine is classified here.

➤ Chlorbenzoxamine is classified in A2B9.

➤ Trimebutine is classified here.

➤ Trimebutine is classified in A3F.

➤ Alosetron is classified here (A03A E).

➤ Alosetron is classified in A3G.

+

A03B BELLADONNA AND DERIVATIVES, PLAIN

❖

A03C ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS

A3C ANTISPASMODIC/ATARACTIC COMBINATIONS

A03D ANTISPASMODICS IN COMBINATION WITH ANALGESICS

A3D ANTISPASMODIC/ANALGESIC COMBINATIONS

➤ Combinations with both psycholeptics and analgesics are classified in A03E A.

➤ Combination of both ataractic and analgesic are classified here.

A03E ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS

A03E A Antispasmodics, psycholeptics and analgesics in combination

➤ Antispasmodics in combination with psycholeptics, analgesics and other agents are classified in this group.

➤ Combinations of both ataractics and analgesics are classified in A3D.

A03E D Antispasmodics in combination with other drugs

A3E ANTISPASMODICS COMBINED WITH OTHER PRODUCTS

A03F PROPULSIVES

A3F GASTROPROKINETICS

WHO (Substance based)

EphMRA (Product based)

	➤ Trimebutine is classified in A03A.		➤ Trimebutine is classified here.
❖	<ul style="list-style-type: none"> ➤ Alosetron is classified in A03A E. ➤ Tegaserod is classified in A06A X. ➤ Linaclotide is classified in A06A X. ➤ Lubiprostone is classified in A06A X. 	A3G	GASTRO-INTESTINAL SENSORIMOTOR MODULATORS <ul style="list-style-type: none"> ➤ Alosetron is classified here. ➤ Tegaserod is classified here. ➤ Linaclotide is classified here when indicated in IBS-c (290mcg), but in A6A when indicated in chronic constipation (145mcg). ➤ Lubiprostone is classified here when indicated in IBS-c (8mcg), but in A6A when indicated in chronic constipation (24mcg).
A04	ANTIEMETICS AND ANTINAUSEANTS	A4	ANTIEMETICS AND ANTINAUSEANTS
A04A	ANTIEMETICS AND ANTINAUSEANTS <ul style="list-style-type: none"> ➤ Antihistamines are classified in R06A. 	A4A	ANTIEMETICS AND ANTINAUSEANTS <ul style="list-style-type: none"> ➤ Antihistamines used in motion sickness are classified here.
A05	BILE AND LIVER THERAPY	A5	CHOLAGOGUES AND HEPATIC PROTECTORS
A05A	BILE THERAPY	A5A	BILE THERAPY AND CHOLAGOGUES
A05B	LIVER THERAPY, LIPOTROPICS	A5B	HEPATIC PROTECTORS, LIPOTROPICS
A05C	DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION	A5C	CHOLAGOGUE/LIPOTROPIC COMBINATIONS
A06	LAXATIVES	A6	LAXATIVES AND BOWEL CLEANSERS
A06A	LAXATIVES <ul style="list-style-type: none"> ➤ Tegaserod is classified here. ➤ Linaclotide is classified here. ➤ Lubiprostone is classified here. 	A6A	LAXATIVES <ul style="list-style-type: none"> ➤ Tegaserod is classified in A3G. ➤ Linaclotide is classified here when indicated in chronic constipation (145mcg) but in A3G when indicated in IBS-c (290mcg).

WHO (Substance based)

EphMRA (Product based)

- Lubiprostone is classified here when indicated in chronic constipation (24mcg) but in A3G when indicated in IBS-c (8mcg).

A6B BOWEL CLEANSERS

WHO (Substance based)

EphMRA (Product based)

A07 **ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY / ANTIINFECTIVE AGENTS**

A7 **ANTIDIARRHOEALS, ORAL ELECTROLYTE REPLACERS AND INTESTINAL ANTIINFLAMMATORIES**

A07A INTESTINAL ANTIINFECTIVES

A7A INTESTINAL ANTIINFECTIVE ANTIDIARRHOEALS

A07B INTESTINAL ADSORBENTS
➤ Ceratonia is classified in A07X.

A7B INTESTINAL ABSORBANT ANTIDIARRHOEALS
➤ Ceratonia is classified here.

A07C ELECTROLYTES WITH CARBOHYDRATES

A7G ORAL ELECTROLYTE REPLACERS

A07D ANTIPROPULSIVES

A7H MOTILITY INHIBITORS

A07E INTESTINAL ANTIINFLAMMATORY AGENTS

A7E INTESTINAL ANTIINFLAMMATORY AGENTS

A07F ANTIDIARRHEAL MICROORGANISMS

A7F ANTIDIARRHOEAL MICRO-ORGANISMS

A07X OTHER ANTIDIARRHEALS
➤ Ceratonia is classified here.

A7X ALL OTHER ANTIDIARRHOEALS
➤ Ceratonia is classified in A7B.

A08 **ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS**

A8 **ANTIOBESITY PREPARATIONS, EXCL. DIETETICS**

A08A ANTI OBESITY PREPARATIONS, EXCL. DIET PRODUCTS
➤ Amphetamine is classified in N06B.

A8A ANTI OBESITY PREPARATIONS, EXCL. DIETETICS
➤ Amphetamine, when indicated as antiobesity product, is classified here.

A09 **DIGESTIVES, INCL. ENZYMES**

A9 **DIGESTIVES, INCL. DIGESTIVE ENZYMES**

A09A DIGESTIVES, INCL. ENZYMES
➤ Bromelains is classified in B06A A.
➤ Chymotrypsin and trypsin are classified in B06A A when used as haematological enzymes.

A9A DIGESTIVES, INCL. DIGESTIVE ENZYME
➤ Bromelains is classified here or, D3A and V3H depending on indications.
➤ Chymotrypsin is classified here or in C5B, D3A, M2A and V3H depending on indications.

WHO (Substance based)

EphMRA (Product based)

- Trypsin is classified here or in V3H and V3X depending on indications.

A10 DRUGS USED IN DIABETES

A10A INSULINS and ANALOGUES

A10B ORAL BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS

- Guar gum is classified here.
- Exenatide is classified here (A10B X).

A10X OTHER DRUGS USED IN DIABETES

Includes aldose reductase inhibitors.

- Guar gum is classified in A10B.
- Thiocctic acid is classified in A16A.
- Combinations of DPP-IV inhibitors with statins are classified in A10B H.

A10 DRUGS USED IN DIABETES

A10C HUMAN INSULINS and ANALOGUES

+

A10D ANIMAL INSULINS

A10H SULPHONYLUREA ANTIDIABETICS
A10J BIGUANIDE ANTIDIABETICS
A10J1 BIGUANIDE ANTIDIABETICS, PLAIN
A10J2 BIGUANIDE AND SULPHONYLUREA ANTIDIABETIC COMBINATIONS
A10J9 BIGUANIDE ANTIDIABETIC COMBINATIONS, OTHER
A10K GLITAZONE ANTIDIABETICS
A10K1 GLITAZONE ANTIDIABETICS, PLAIN
A10K2 GLITAZONE AND SULPHONYLUREA ANTIDIABETIC COMBINATIONS
A10K3 GLITAZONE AND BIGUANIDE ANTIDIABETIC COMBINATIONS
A10K9 GLITAZONE ANTIDIABETIC COMBINATIONS, OTHER
A10L ALPHA-GLUCOSIDASE INHIBITOR ANTIDIABETICS
A10M GLINIDE ANTIDIABETICS
A10M1 GLINIDE ANTIDIABETICS, PLAIN
A10M3 GLINIDE AND BIGUANIDE ANTIDIABETIC COMBINATIONS
A10M9 GLINIDE ANTIDIABETIC COMBINATIONS, OTHER
A10N DPP-IV INHIBITOR ANTIDIABETICS
A10N1 DPP-IV INHIBITOR ANTIDIABETICS, PLAIN
A10N3 DPP-IV INHIBITOR AND BIGUANIDE ANTIDIABETIC COMBINATIONS
A10N9 DPP-IV INHIBITOR ANTIDIABETIC COMBINATIONS, OTHER
A10S GLP-1 AGONIST ANTIDIABETICS

A10X OTHER DRUGS USED IN DIABETES

A10X1 Antidiabetic multitherapy combination products

Includes combinations of antidiabetics with cardiovascular drugs where the aim is to treat both the diabetes and the cardiovascular condition. Also includes combinations of antidiabetics with anti-obesity drugs where the aim is to treat both the diabetes and the obesity.

WHO (Substance based)

EphMRA (Product based)

A10X9

Other drugs used in diabetes.

- Guar gum is classified here..
- Thiocotic acid is classified here or A16A.

A11 VITAMINS

- Vitamin B₁₂ is classified in B03.

A11 VITAMINS

- Vitamin B₁₂ is classified in A11F, which is a code only used in the EphMRA/PBIRG system.

A12 MINERAL SUPPLEMENTS

A12A CALCIUM

A12B POTASSIUM

A12C OTHER MINERAL SUPPLEMENTS

A12 MINERAL SUPPLEMENTS

A12A CALCIUM PRODUCTS

A12B POTASSIUM PRODUCTS

A12C OTHER MINERAL SUPPLEMENTS

A13 TONICS

A13A TONICS

A13 TONICS

A13A TONICS

The large number of products in this class make it impossible to fully state that they are equal.

A14 ANABOLIC AGENTS FOR SYSTEMIC USE

A14A ANABOLIC STEROIDS

A14B OTHER ANABOLIC AGENTS

A14 ANABOLICS, SYSTEMIC

A14A ANABOLIC HORMONES, SYSTEMIC

A14B OTHER ANABOLIC AGENTS, SYSTEMIC

A15 APPETITE STIMULANTS

- Cyproheptadine is classified in R06A.
- Pizotifen is classified in N02C.

A15 APPETITE STIMULANTS

- Cyproheptadine when indicated as appetite stimulant, is classified here, otherwise it is classified in R6A.

WHO (Substance based)

EphMRA (Product based)

-
-
- Pizotifen is classified here; when indicated for migraine, is classified in N2C.
-
-

A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

- Includes levocarnitine, ademetionine, thioctic acid.
- Zinc acetate is classified here.

A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

- Levocarnitine is classified here but when indicated for ischaemic disorders, it is classified in C1X.
 - Ademetionine is classified in N6A.
 - Thioctic acid is classified here or in A10X.
 - Combinations of diabetes and cardiovascular products are classified in A10X1.
 - Zinc acetate is classified in V3E when indicated for Wilson's disease.
-

WHO (Substance based)

B	BLOOD AND BLOOD FORMING ORGANS
B01	ANTITHROMBOTIC AGENTS
B01A	ANTITHROMBOTIC AGENTS
☞	
B01A A	Vitamin K antagonists
B01A B	Heparin group
	➤ Antithrombin III is classified here.
	➤ Danaparoid is classified here.
B01A C	Platelet aggregation inhibitors excl. heparin
	➤ Dipyridole is classified here.
	➤ Defibrotide is classified in B01A X.
B01A D	Enzymes
☞	➤ Protein C and activated Protein C are classified here.
B01A E	Direct thrombin inhibitors
B01A F	Direct factor Xa inhibitors
B01A X	Other antithrombotic agents
	➤ Defibrotide is classified here.

EphMRA (Product based)

B	BLOOD AND BLOOD FORMING ORGANS
B1	ANTITHROMBOTIC AGENTS
☞	
B1A	VITAMIN K ANTAGONISTS
B1B	HEPARINS
	➤ Antithrombin III is classified in B2C.
	➤ Danaparoid is classified in B1X.
B1C	PLATELET AGGREGATION INHIBITORS
	➤ Dipyridole is classified here; when indicated for coronary therapy it is classified in C1D.
	➤ Defibrotide is classified here.
B1D	FIBRINOLYTICS
☞	➤ Protein C and activated Protein C are classified in B1X.
B1E	DIRECT THROMBIN INHIBITORS
B1F	DIRECT FACTOR XA INHIBITORS
B1X	OTHER ANTITHROMBOTIC AGENTS
	➤ Defibrotide is classified in B1C.

WHO (Substance based)

EphMRA (Product based)

B02 ANTIHEMORRHAGICS

B02A ANTIFIBRINOLYTICS

B02A A Amino acids

B02A B Proteinase inhibitors

- C-1 inhibitor, ecallantide and conestat alfa are classified in B06AC.
- Alfa 1 antitrypsin (alpha-1-proteinase inhibitor) is classified here.

B02B VITAMIN K AND OTHER HEMOSTATICS

B02B A Vitamin K

- Protamin is classified in V03A.

B02B B Fibrinogen

B02B C Local hemostatics

B02B D Blood coagulation factors

❖

- Eltrombopag and romiplostim are classified in B02B X.

B02B X Other systemic hemostatics

- Eltrombopag and romiplostim are classified here.

B03 ANTIANEMIC PREPARATIONS

B03A IRON PREPARATIONS

- All plain iron preparations and all combination products containing more than 30 mg Fe per defined daily dose (DDD), are

B2 BLOOD COAGULATION SYSTEM, OTHER PRODUCTS

B2A ANTIFIBRINOLYTICS

B2C PROTEINASE INHIBITORS

- C-1 inhibitor, ecallantide and conestat alfa are classified here.
- Alpha-1-proteinase inhibitor (alfa 1 antitrypsin) is classified in R3X.

B2B ANTAGONISTS (ANTIDOTES TO ANTICOAGULANTS)

B2B1 Vitamin K

B2B2 Protamin sulphate

B2F TISSUE SEALING PREPARATIONS

- Local hemostatics are classified in D3A

B2D BLOOD COAGULATION

B2E THROMBOPOIETIN AGONISTS

- Eltrombopag and romiplostim are classified here.

B2G SYSTEMIC HAEMOSTATICS

- Eltrombopag and romiplostim are classified in B2E.

B3 ANTI-ANAEMIC PREPARATIONS

B3A HAEMATINICS, IRON & ALL COMBINATIONS

- Combinations of iron with multivitamins are classified in A11A.

WHO (Substance based)

EphMRA (Product based)

classified here, even if they contain multivitamins.

B03B VITAMIN B12 AND FOLIC ACID



B03B A Vitamin B12 (cyanocobalamin and analogues)

B03B B Folic acid and derivatives

➤ Folinic acid is classified in V03A.

B03X OTHER ANTIANEMIC PREPARATIONS

B03X A Other antianemic preparations



B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS

B05A BLOOD AND RELATED PRODUCTS

B05A A Blood substitutes and plasma protein fractions

B05B I.V. SOLUTIONS

B05B A Solutions for parenteral nutrition

+

B05B B Solutions affecting the electrolyte balance

➤ Trometamol is classified here.

B05B C Solutions producing osmotic diuresis

B3B LIVER EXTRACTS AND COMBINATIONS WITH B12

A11F PLAIN VIT B12

B3X OTHER ANTI-ANAEMIC PRODUCTS, INCLUDING FOLIC ACID, FOLINIC ACID

➤ Folinic acid with more than one indication classified in V3D.

B3C ERYTHROPOIETIN PRODUCTS

K HOSPITAL SOLUTIONS



K3B PROTEIN SOLUTIONS

+

K2 PLASMA EXPANDERS

K1 INTRAVENOUS SOLUTIONS

➤ Trometamol is classified in K4B.

K1F SOLUTIONS FOR OSMOTIC THERAPY

WHO (Substance based)

EphMRA (Product based)

B05C	IRRIGATING SOLUTIONS	K5	IRRIGATING SOLUTIONS
B05D	PERITONEAL DIALYTICS	K6B	PERITONEAL DIALYSIS SOLUTIONS
B05X	I.V. SOLUTION ADDITIVES	K4	INJECTION SOLUTIONS/INFUSION ADDITIVES
B05Z	HEMODIALYTICS AND HEMOFILTRATES		
B05Z A	Hemodialytics, concentrates	K6A	HAEMODIALYSIS SOLUTIONS
B05Z B	Hemofiltrates	K6C	HAEMOFILTRATION
B06	OTHER HEMATOLOGICAL AGENTS	B6	ALL OTHER HAEMATOLOGICAL AGENTS
B06A	OTHER HEMATOLOGICAL AGENTS	❖	
B06A A	Enzymes	B6B	HYALURONIDASE
	➤ Bromelains is classified here.	+	
	➤ Chymotrypsin and trypsin are classified here when used as haematological enzymes.	B6C	OTHER HEMATOLOGICAL AGENTS
			➤ Bromelains is classified in A9A, D3A or V3H depending on indications.
			➤ Chymotrypsin is classified in A9A, C5B, D3A, M2A or V3H depending on indications.
			➤ Trypsin is classified in A9A, V3H or V3X depending on indications.
B06A B	Other hem products	B6C	OTHER HEMATOLOGICAL AGENTS
	➤ Ruxolitinib is classified in L01XE.		➤ Ruxolitinib is classified here.

WHO (Substance based)

EphMRA (Product based)

C **CARDIOVASCULAR SYSTEM**

C01 CARDIAC THERAPY

C01A CARDIAC GLYCOSIDES

C01B ANTIARRHYTHMICS, CLASS I AND III

- Adenosine is classified in C01E

C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES

C01C A Adrenergic and dopaminergic agents

- Caffeine, plain is classified in N06B.
- Heptaminol is classified in C01D.
- Dihydroergotamine is classified in N02C.

C01C E Phosphodiesterase Inhibitors



+

C01C X Other cardiac stimulants

C01D VASODILATORS USED IN CARDIAC DISEASES

C01D A Organic nitrates

- Amyl nitrite is classified in V03A.

C01D B Quinolone vasodilators

- Flosequinan is classified here.

C **CARDIOVASCULAR SYSTEM**

C1 CARDIAC THERAPY

C1A CARDIAC GLYCOSIDES AND COMBINATIONS

C1B ANTI-ARRHYTHMICS

- Adenosine is classified here

C1C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES

- Caffeine, plain is classified here.
- Heptaminol is classified here.
- Dihydroergotamine is classified here and in N2C.

C1F POSITIVE INOTROPIC AGENTS

Includes substances such as amrinone, milrinone, fenoximone, piroximone, xamoterol.

C1E NITRITES AND NITRATES

- Amyl nitrite is classified here and V3A.



- Flosequinan is classified in C1D.

WHO (Substance based)

EphMRA (Product based)

- C01D X Other Vasodilators used in cardiac diseases
- Prenylamine is classified here.
 - Heptaminol is classified here.
 - Dipyramidol is classified in B01A C.
 - Trimetazidine is classified in C01E B.
 - Ivabradine is classified in C01E B.
 - Flosequinan is classified in C01D B.

- C1D CORONARY THERAPY EXCL. CALCIUM ANTAGONISTS AND NITRITES
- Prenylamine is classified in C8A.
 - Heptaminol is classified in C1C.
 - Dipyramidol is classified here and in B1C.
 - Trimetazidine is classified here.
 - Ivabradine is classified here.
 - Flosequinan is classified here.

- C01E OTHER CARDIAC PREPARATIONS
- Adenosine is classified here.
 - Levocarnitine is classified in A016.
 - Trimetazidine is classified here.
 - Ivabradine is classified here.

- C1X ALL OTHER CARDIAC PREPARATIONS
- Adenosine is classified in C1B.
 - Levocarnitine is classified in this group when indicated for ischaemic disorders (in A16 if for nutrition problems).
 - Ivabradine is classified in C1D.

- C02 ANTIHYPERTENSIVES**
- Mebutamate is classified in N05B.
 - Terazosin is classified in G04C.
 - Bosentan is classified here.

- C2 ANTIHYPERTENSIVES**
- Mebutamate is classified in C2A.
 - Terazosin is classified here and in G4C.
 - Bosentan is classified in C6A.

- C03 DIURETICS**
- Cicletanine is classified here.

- C3 DIURETICS**
- Cicletanine is classified in C2A.

- C04 PERIPHERAL VASODILATORS**

- C4 CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS**

WHO (Substance based)

EphMRA (Product based)

- C04A PERIPHERAL VASODILATORS
- Cinnarizine and flunarizine are classified in N07C.
 - Nimodipine is classified in C08.
 - Citicoline is classified in N06B.
 - Visnadine is classified here.

- C4A CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS
- Cinnarizine and flunarizine can be classified here and also in N2C and N7C depending on indications.
 - Nimodipine is classified here.
 - Citicoline is classified here.
 - Visnadine is classified in C1D.

C05 VASOPROTECTIVES

C5 ANTIVARICOSIS/ANTIHAEMORRHOIDAL PREPARATIONS

C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE

C5A TOPICAL ANTI-HAEMORRHOIDALS

C05B ANTIVARICOSE THERAPY

- Chymotrypsin is classified in B06A A when used as haematological enzymes.

C5B VARICOSE THERAPY, TOPICAL

- Chymotrypsin is classified here or in A9A, D3A, M2A and V3H depending on indications.

C05C CAPILLARY STABILIZING AGENTS

C5C VARICOSE THERAPY, SYSTEMIC



- Bosentan is classified in C02K.
- Iloprost is classified here or in B01A .
- Sildenafil is classified in G04B .
- Icatibant is classified in B06A C.

C6 OTHER CARDIOVASCULAR PRODUCTS

- Bosentan is classified here.
- Iloprost is classified here or in B1C depending on indication.
- Sildenafil is classified here or in G4E depending on indication.
- Icatibant is classified here.

C07 BETA BLOCKING AGENTS

C7 BETA BLOCKING AGENTS

C07A BETA BLOCKING AGENTS

C7A BETA BLOCKING AGENTS, PLAIN

WHO (Substance based)

EphMRA (Product based)

C07B BETA BLOCKING AGENTS AND THIAZIDES
+
C07C BETA BLOCKING AGENTS AND OTHER DIURETICS
+
C07D BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS
+
C07E BETA BLOCKING AGENTS AND VASODILATORS

C7B BETA BLOCKING AGENTS, COMBINATIONS

C07F BETA BLOCKING AGENTS AND OTHER ANTIHYPERTENSIVES
➤ Combinations with calcium channel blockers are classified here.



- Combinations with calcium channel blockers are classified in C8B.
- Combinations with ACE inhibitors are classified in C9B.
- Combinations with angiotensin-II inhibitors are classified in C9D.

C08 CALCIUM CHANNEL BLOCKERS
➤ Nimodipine is classified here.
➤ Prenylamine is classified in C01D X.
➤ Combinations with beta blockers are classified in C07F.

C8 CALCIUM ANTAGONISTS
➤ Nimodipine is classified in C4A.
➤ Prenylamine is classified here.
➤ Combinations with beta blockers are classified in C8B2.

C08C SELECTIVE CCB WITH MAINLY VASCULAR EFFECT
+
C08D SELECTIVE CCB WITH DIRECT CARDIAC EFFECTS
+
C08E NON-SELECTIVE CALCIUM CHANNEL BLOCKERS

C8A CALCIUM ANTAGONISTS, PLAIN

WHO (Substance based)

EphMRA (Product based)

C8G CALCIUM CHANNEL BLOCKERS AND DIURETICS



C8B1 CALCIUM ANTAGONISTS COMBINATIONS WITH ANTIHYPERTENSIVES (C2) AND/OR DIURETICS

C8B2 CCB/BETABLOCKER COMBINATIONS

C8B3 CCB COMB. WITH OTHER DRUGS OF GROUP C, except C7-C10

C8B4 CCB COMBINATIONS WITH ALL OTHER DRUGS

C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

C9 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

C09A ACE INHIBITORS, PLAIN

C9A ACE INHIBITORS, PLAIN

C09B ACE INHIBITORS, COMBINATIONS
➤ Combinations with beta-blockers are classified in C07F.

C9B ACE INHIBITORS, COMBINATIONS S
➤ Combinations with beta-blockers are classified here.

C09C ANGIOTENSIN II ANTAGONISTS, PLAIN

C9C ANGIOTENSIN II ANTAGONISTS, PLAIN

C09D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
➤ Combinations with beta-blockers are classified in C07F.

C9D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
➤ Combinations with beta-blockers are classified here.

C09X OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

C9X OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

C10 LIPID MODIFYING AGENTS

C10 LIPID-REGULATING/ANTI-ATHEROMA PREPARATIONS

C10A LIPID MODIFYING AGENTS, PLAIN

C10A CHOLESTEROL AND TRIGLYCERIDE REGULATING PREPARATIONS

C10A A HMG CoA reductase inhibitors

C10A 1 Statins (HMG-CoA reductase inhibitors)

C10A B Fibrates

C10A 2 Fibrates

WHO (Substance based)

EphMRA (Product based)

C10A C Bile acid sequestrants

C10A D Nicotinic acid and derivatives

+

C10A X Other lipid modifying agents



C10B LIPID MODIFYING AGENTS, COMBINATIONS

- Lipid-regulating cardiovascular multitherapy combination products are classified here.



- ❖ ➤ Lipid-regulating cardiovascular multitherapy combination products are classified in C10B

C10A 3 Ion-exchange resins

C10A 9 All other cholesterol/triglyceride regulators

C10 B ANTI-ATHEROMA PREPARATIONS OF NATURAL ORIGIN

C10C LIPID REGULATORS IN COMBINATION WITH OTHER LIPID REGULATORS

- Lipid-regulating cardiovascular multitherapy combination products are classified in C11A.

C11 CARDIOVASCULAR MULTI-THERAPY COMBINATION PRODUCTS

C11A LIPID-REGULATING CARDIOVASCULAR MULTI-THERAPY COMBINATION PRODUCTS

WHO (Substance based)

EphMRA (Product based)

D DERMATOLOGICALS

D01 ANTIFUNGALS FOR DERMATOLOGICAL USE

D01A ANTIFUNGALS FOR TOPICAL USE

- Topical metronidazole is mainly used for rosacea and is classified in D06B X.
- Combinations with corticosteroids are classified here.

D01B ANTIFUNGALS FOR SYSTEMIC USE

- Terbinafine is classified here.

D02 EMOLLIENTS AND PROTECTIVES

D02A EMOLLIENTS AND PROTECTIVES

- + ➤ Aminobenzoic acid is classified in D02B.

D02B PROTECTIVES AGAINST UV-RADIATION

- Betacarotene is classified here.
 - Aminobenzoic acid is classified here.
-

D DERMATOLOGICALS

D1 ANTIFUNGALS, DERMATOLOGICAL

D1A1 Topical dermatological antifungals

- Products indicated for the treatment of rosacea are classified in D10A.
- Combinations with corticosteroids are in D7B2.

D1A2 Systemic dermatological Antifungals

- Terbinafine is classified in J2A.

D2 EMOLLIENTS, PROTECTIVES

D2A EMOLLIENTS, PROTECTIVES

- Aminobenzoic acid is classified here.

- Betacarotene is classified in D11A.
-

WHO (Substance based)

EphMRA (Product based)

D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS

- Local haemostatics are classified in B02B.
- Bromelains is classified in B06A A.
- Chymotrypsin is classified in B06A A when used as haematological enzymes.

D3 WOUND HEALING AGENTS

- Local haemostatics are classified here.
- Bromelains is classified here or in A9A and V3H depending on indications.

D03A CICATRIZANTS



D03B ENZYMES



D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.

D4 ANTIPRURITICS, INCL. TOPICAL ANTIHISTAMINES, ANAESTHETICS, ETC.

D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC

- Nalfurafine is classified in V03A.

D4A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANAESTHETICS, ETC.

- Nalfurafine is classified here.

D05 ANTIPSORIATICS

D5 NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS

D05A ANTIPSORIATICS FOR TOPICAL USE

D5A TOPICAL ANTIPSORIASIS PRODUCTS

D05B ANTIPSORIATICS FOR SYSTEMIC USE

- Alefacept is classified in L04A.
- Methotrexate is classified in L01B and L04A.
- Ustekinumab is classified in L04A.

D5B SYSTEMIC ANTIPSORIASIS PRODUCTS

- Alefacept is classified here.
 - Methotrexate is classified in D5B, M1C and L1B.
 - Ustekinumab is classified here.
-

WHO (Substance based)

EphMRA (Product based)

WHO (Substance based)

EphMRA (Product based)

<p>❖</p> <ul style="list-style-type: none"> ➤ Topical tacrolimus is classified in D11A. ➤ Alitretinoin is classified in D11A. ➤ Aminolevulinic acid is classified in L01X. 	<p>D5X OTHER NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS</p> <ul style="list-style-type: none"> ➤ Topical tacrolimus is classified here. ➤ Alitretinoin is classified in here when indicated for the treatment of eczema, and in L1X1 when indicated to treat cutaneous lesions in Kaposi's sarcoma. ➤ Aminolevulinic acid is classified here and in L1X.
<p>D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE</p> <ul style="list-style-type: none"> ➤ Metronidazole for the treatment of rosacea is classified here. ➤ Dressings with anti-infectives are classified in D09A A. 	<p>D6 TOPICAL ANTIBACTERIALS AND ANTIVIRALS</p> <ul style="list-style-type: none"> ➤ Metronidazole for treatment of rosacea is classified in D10A. ➤ Dressings with anti-infectives are classified here.
<p>D06A ANTIBIOTICS FOR TOPICAL USE</p>	<p>D6A TOPICAL ANTIBACTERIALS</p>
<p>D06B CHEMOTHERAPEUTICS FOR TOPICAL USE (- D6B B)</p>	<p>D6A TOPICAL ANTIBACTERIALS</p>
<p>D06B B Antivirals</p>	<p>D6D TOPICAL ANTIVIRALS INFECTION PRODUCTS</p>
<p>D6C ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS</p>	<p>❖ Included in D6A</p>

WHO (Substance based)

EphMRA (Product based)

D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

D7 TOPICAL CORTICOSTEROIDS

D07A CORTICOSTEROIDS, PLAIN

D7A PLAIN TOPICAL CORTICOSTEROIDS

D07B CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS

D7B TOPICAL CORTICOSTEROID COMBINATIONS

+

D07C CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS ❖

+

D07X CORTICOSTEROIDS, OTHER COMBINATIONS ❖

D08 ANTISEPTICS AND DISINFECTANTS

D8 ANTISEPTICS AND DISINFECTANTS

D08A ANTISEPTICS AND DISINFECTANTS

D8A ANTISEPTICS AND DISINFECTANTS

D09 MEDICATED DRESSINGS

❖ THE PRODUCTS OF THIS CLASS HAVE BEEN ALLOCATED TO THE DIFFERENT GROUPS



D09A MEDICATED DRESSINGS

This group comprises medicated dressings, ointment dressings etc. Liquid wound protectives are classified in D02A D – Liquid plasters. Local hemostatics, eg. Gauze, tampons etc. are classified in B02B C – Local hemostatics.

D09A A Ointment dressings with antiinfectives

Included in D6A

TOPICAL ANTIBIOTICS AND/OR SULPHONAMIDES

WHO (Substance based)

EphMRA (Product based)

D09A B Zinc bandages

Included
in
D5A

TOPICAL ANTIPSORIASIS AND SIMILAR PRODUCTS

D09A X Soft paraffin dressings

Included
in
D2A

EMOLLIENTS, PROTECTIVES

D10 ANTI-ACNE PREPARATIONS

D10 ANTI-ACNE PREPARATIONS

D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE

D10A TOPICAL ANTI-ACNE PREPARATIONS

- Metronidazole for the treatment of rosacea is classified in D06B.

- Metronidazole for the treatment of rosacea is classified here

D10B ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE

D10B ORAL ANTI-ACNE PREPARATIONS

- Antibiotics, such as tetracyclines and erythromycin, which are also used for the treatment of acne are classified in group J.
- Combinations of estrogen and antiandrogen, used for the treatment of acne, are classified in group G03H.

- Antibiotic products, specifically indicated for the treatment of acne are classified here.
 - Combinations of estrogen and cyproterone, specifically indicated for the treatment of acne, are classified here.
-

WHO (Substance based)

EphMRA (Product based)

D11 OTHER DERMATOLOGICAL PREPARATIONS

D11A OTHER DERMATOLOGICAL PREPARATIONS

- Androgens for topical use are classified here.
- Tacrolimus and pimecrolimus are classified here.
- Alitretinoin is classified here.

D11 OTHER DERMATOLOGICAL PREPARATIONS

D11A OTHER DERMATOLOGICAL PREPARATIONS

- Androgens for topical use are in D3A.
 - Tacrolimus is classified in D5X and L4A; pimecrolimus in D5X.
 - Alitretinoin is classified in D5X when indicated for the treatment of eczema, and in L1X1 when indicated to treat cutaneous lesions in Kaposi's sarcoma.
-

WHO (Substance based)

EphMRA (Product based)

G GENITO URINARY SYSTEM AND SEX HORMONES

G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS

- All oral and rectal dosage forms of imidazole derivatives are classified in P01A.

G02 OTHER GYNAECOLOGICALS

- Analgesics used in dysmenorrhea are classified in N02B.

G02A OXYTOCICS

- Oxytocin and demoxytocin are classified in H01B.

G02B CONTRACEPTIVES FOR TOPICAL USE

- IUDs containing progestogens are classified here.

G02C OTHER GYNECOLOGICALS

- Vaginal forms of estrogens are classified in G03C.

G02C A Sympathomimetics, labor repressants

❖

- Vaginal forms of estrogens are classified in G03C.

G GENITO-URINARY SYSTEM AND SEX HORMONES

G1 GYNAECOLOGICAL ANTI-INFECTIVES

- Dosage forms used for treatment of gynaecological infections are classified here.

G2 OTHER GYNAECOLOGICALS

- Analgesics indicated exclusively for dysmenorrhea are classified in G2X1.

G2A LABOUR INDUCERS

- Oxytocin and demoxytocin are classified here.

G2B TOPICAL CONTRACEPTIVES

- IUDs with progestogens are classified in G3A.

❖

- Vaginal forms of estrogens are classified in G2F.

G2E LABOUR INHIBITORS

G2F TOPICAL SEX HORMONES

- Vaginal forms of estrogens are classified here.

WHO (Substance based)

EphMRA (Product based)

G02C B	Prolactin inhibitors <ul style="list-style-type: none">➤ Lisuride tablets in high strength (0.2mg) are classified in this group, while low dose tablets (25 mcg) are classified in N02C.➤ Bromocriptine low dose is classified here; high strength tablets are classified in N04B.➤ Cabergoline low dose is classified here, high strength tablets are classified in N04B.
G02C C	Antiinflammatory products for vaginal administration
+	
G02C X	Other gynaecologicals

G2D	PROLACTIN INHIBITORS <ul style="list-style-type: none">➤ Lisuride is classified in N4A.➤ Bromocriptine is classified here and N4A.➤ Cabergoline is classified here and N4A.
G2X	OTHER GYNAECOLOGICAL PRODUCTS

G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

G3 SEX HORMONES AND PRODUCTS WITH SIMILAR DESIRED EFFECTS, SYSTEMIC ACTION ONLY

G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE <ul style="list-style-type: none">➤ IUDs with progestogens are classified in G02B.
------	---

G3A	HORMONAL CONTRACEPTIVES, SYSTEMIC <ul style="list-style-type: none">➤ IUDs with progestogens are classified here.
-----	---

G03B	ANDROGENS
------	-----------

G3B	ANDROGENS, EXCLUDING G3E, G3F
-----	-------------------------------

G03C	ESTROGENS <ul style="list-style-type: none">➤ Tibolone is classified here.➤ Vaginal forms are classified here.
------	---

G3C	OESTROGENS, EXCLUDING G3A, G3E, G3F <ul style="list-style-type: none">➤ Tibolone is classified G3X.➤ Vaginal forms are classified G2F.
-----	---

G03D	PROGESTOGENS <ul style="list-style-type: none">➤ Flumedroxone is classified in N02C.
------	---

G3D	PROGESTOGENS, EXCLUDING G3A,G3F <ul style="list-style-type: none">➤ Flumedroxone is classified here.
-----	--

WHO (Substance based)

EphMRA (Product based)

G03E	ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION	G3E	ANDROGEN WITH FEMALE HORMONE COMBINATIONS
G03F	PROGESTOGENS AND ESTROGENS IN COMBINATION ➤ Estradiol and cyproterone in combination is classified in G03H B.	G3F	OESTROGEN WITH PROGESTOGEN COMBINATIONS, EXCLUDING G3A ➤ Estradiol and cyproterone in combination is classified here.
G03G	GONADOTROPHINS AND OTHER OVULATION STIMULANTS	G3G	GONADOTROPHINS, INCL.OTHER OVULATION STIMULANTS
G03H	ANTIANDROGENS ➤ All plain cyproterone preparations (and combinations of cyproterone and estrogen) regardless of indication are classified here.	❖	➤ Plain cyproterone preparations are classified in G3X and L2B depending on indication.
❖	➤ Bazedoxifene, lasofoxifene and raloxifene are classified in G03X.	G3J	SERMS (SELECTIVE OESTROGEN RECEPTOR MODULATORS) ➤ Bazedoxifene, lasofoxifene and raloxifene are classified here.
G03X	OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ➤ Tibolone is classified in G03D C. ➤ Bazedoxifene, lasofoxifen and raloxifene are classified here. ➤ All plain cyproterone preparations (and combinations of cyproterone and estrogen) regardless of indication are classified in G03H.	G03X	OTHER SEX HORMONES AND SIMILAR PRODUCTS ➤ Tibolone is classified here ➤ Products containing cyproterone are classified according to indication. ➤ Combinations of estrogen and cyproterone are classified in D10B (DIANE 35) and G3F (CLIMEN). ➤ Bazedoxifene, lasofoxifen and raloxifene are classified in G3J. ➤ Plain cyproterone preparations are classified here and in L2B depending on indication.

WHO (Substance based)

EphMRA (Product based)

G04	UROLOGICALS	G4	UROLOGICALS
❖	<ul style="list-style-type: none"> ➤ Urinary quinolones are in J01M. ➤ Other urinary antibacterials are in J01X. 	G4A	URINARY ANTI-INFECTIVES AND ANTISEPTICS <ul style="list-style-type: none"> ➤ Urinary quinolones are here in G4A2. ➤ Halogenated quinolones are in G4E. ➤ Other antiseptics and anti-bacterials are here in G4A9.
G04B	OTHER UROLOGICALS, INCL. ANTISPASMODICS <ul style="list-style-type: none"> ➤ Drugs used in erectile dysfunction are here in G04B E. ➤ Urinary antispasmodics are here in G04B D. 	❖	<ul style="list-style-type: none"> ➤ Other urologicals are in G4X with exceptions below. ➤ Erectile dysfunction products are in G4E. ➤ Urinary incontinence products are in G4D.
G04C	DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY	G4C	BPH (BENIGN PROSTATIC HYPERTROPHY) PRODUCTS
❖		G4D	URINARY INCONTINENCE PRODUCTS
❖	<ul style="list-style-type: none"> ➤ Phentolamine used as an antidote is in V03A. It is only in G04B for erectile dysfunction when in combinations. 	G4E	ERECTILE DYSFUNCTION PRODUCTS <ul style="list-style-type: none"> ➤ Phentolamine for erectile dysfunction is here. It is in V3X when used as an antidote.
❖	<ul style="list-style-type: none"> ➤ Other urologicals are in G04B. 	G4X	ALL OTHER UROLOGICAL PRODUCTS

WHO (Substance based)

EphMRA (Product based)

H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES

The classification of these hormonal products is based according to the origin of the hormones and not according to their indication.

H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES



H01A ANTERIOR PITUITARY LOBE HORMONES and ANALOGUES

H01A A ACTH

H01A B Thyrotrophin

H01A C Somatropin and somatropin agonists



H01A X Other anterior pituitary lobe hormones and analogues

➤ Pegvisomant is classified here.

H01B POSTERIOR PITUITARY LOBE HORMONES

H01B A Vasopressin and analogues

➤ Terlipressin is classified here.

H01B B Oxytocin and analogues

H01C HYPOTHALAMIC HORMONES

H01C A Gonadotrophin-releasing hormones

H01C B Somatostatin and analogues

H SYSTEMIC HORMONAL PREPARATIONS (EXCL. SEX HORMONES)

H1 PITUITARY AND HYPOTHALAMIC HORMONES

H1A ACTH

Included in THYROID PREPARATIONS

H3A

H4C GROWTH HORMONES



➤ Pegvisomant is classified in H1C.



H4D ANTIDIURETIC HORMONES

➤ Terlipressin is classified in B2G.

G2A LABOUR INDUCERS

H1C HYPOTHALAMIC HORMONES

H1C1 GONADOTROPHIN RELEASING HORMONES

H1C2 ANTIGROWTH HORMONES

WHO (Substance based)

EphMRA (Product based)

➤ Pegvisomant is classified here.

H01C C ANTI-GONADOTROPHIN-RELEASING HORMONES

H1C3 ANTIGONADOTROPHIN-RELEASING HORMONES

H02 CORTICOSTEROIDS FOR SYSTEMIC USE

H2 SYSTEMIC CORTICOSTEROIDS

H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN

H2A SYSTEMIC CORTICOSTEROIDS, PLAIN

H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS

H2B SYSTEMIC CORTICOSTEROID COMBINATIONS

H02C ANTIADRENAL PREPARATIONS

❖

➤ Trilostane is classified here.

➤ Trilostane is classified in H4X.

H03 THYROID THERAPY

H3 THYROID THERAPY

H03A THYROID PREPARATIONS

H3A THYROID PREPARATIONS

➤ Thyrotrophin is classified in H01A.

➤ Thyrotrophin is classified here.

H03B ANTITHYROID PREPARATIONS

H3B ANTI-THYROID PREPARATIONS

H03C IODINE THERAPY

H3C IODINE THERAPY

H04 PANCREATIC HORMONES

❖



H04A GLYCOGENOLYTIC HORMONES

H4B GLUCAGON

H05 CALCIUM HOMEOSTASIS

❖

H05A PARATHYROID HORMONES AND ANALOGUES

H4E PARATHYROID HORMONES AND ANALOGUES

H05B ANTI-PARATHYROID HORMONES

❖

WHO (Substance based)

EphMRA (Product based)

H05B A Calcitonin preparations

H4A CALCITONINS

H05B X Other anti-parathyroid agents

H4F ANTIPARATHYROID PRODUCTS

WHO (Substance based)

EphMRA (Product based)

J ANTIINFECTIVES FOR SYSTEMIC USE

J GENERAL ANTI-INFECTIVES SYSTEMIC

J01 ANTIBACTERIALS FOR SYSTEMIC USE

J1 SYSTEMIC ANTIBACTERIALS

J01A TETRACYCLINES

J1A TETRACYCLINES AND COMBINATIONS

➤ Tigecycline is classified here.

➤ Tigecycline is classified in J1X.

J01B AMPHENICOLS

J1B CHLORAMPHENICOL AND COMBINATIONS

J01C BETA-LACTAM ANTIBACTERIALS, PENICILLINS

J1C BROAD SPECTRUM PENICILLINS

+

J1H MEDIUM AND NARROW SPECTRUM PENICILLINS

+

J1L CARBENICILLIN AND SIMILAR TYPES

J01D OTHER BETA LACTAM ANTIBACTERIALS

❖

J1D CEPHALOSPORINS

J01D B-E ➤ First-fourth generation cephalosporins.

J1D1-2 ➤ Oral – injectable cephalosporins.

➤ Loracarbef is classified here in J01D C.

➤ Loracarbef is classified in J1P3.

➤ Other cephalosporins (including ceftobiprole medocaril and ceftaroline fosamil) are classified in J01D I.

➤ Other cephalosporins (including ceftobiprole medocaril and ceftaroline fosamil) are classified here.

J01D F Monobactams

J1P1 Monobactams

J01D H Carbapenems

J1P2 Penems and carbapenems

+

J01D I Other cephalosporins and penems

➤ Other cephalosporins (including ceftobiprole medocaril and ceftaroline fosamil) are classified in J1D.

J01E SULFONAMIDES AND TRIMETHOPRIM

J1E TRIMETHOPRIM AND SIMILAR FORMULATIONS

WHO (Substance based)

EphMRA (Product based)

<u>WHO (Substance based)</u>		<u>EphMRA (Product based)</u>	
		+	
		J3A	SYSTEMIC SULFONAMIDES
J01F	MACROLIDES, LINCOSAMIDES and STREPTOGRAMINS ➤ Pristinamycin is classified here.	J1F	MACROLIDES AND SIMILAR TYPES ➤ Pristinamycin is classified in J1X.
J01G	AMINOGLYCOSIDE ANTIBACTERIALS ➤ Plain streptomycin is classified here.	J1K	AMINOGLYCOSIDES ➤ Streptomycin is classified in J1X.
J01M	QUINOLONE ANTIBACTERIALS	J1G	FLUOROQUINOLONES ➤ Non-halogenated quinolones are in G4A2.
J01R	COMBINATIONS OF ANTIBACTERIALS Sulfonamides, combinations with other antibacterials (excl. trimethoprim) are classified here.	❖	Sulfonamides in combinations with other antibacterials (excl. trimethoprim) are classified in J3A.
❖	➤ Monobactams, carbapenems, carbacephems are classified in J01D.	J1P	OTHER BETA-LACTAM ANTIBACTERIALS, EXCLUDING PENICILLINS, CEPHALOSPORINS ➤ Monobactams, carbapenems, carbacephems are classified here.
J01X	OTHER ANTIBACTERIALS ➤ Pristinamycin is classified J01F ; Tigecyclin is in J01A. ➤ Parenteral imidazole formulations are classified here in J01X D.	J1X	OTHER ANTIBACTERIALS ➤ Pristinamycin and tigecyclin are classified here. ➤ Parenteral imidazole formulations are classified in J8B.
J02	ANTIMYCOTICS FOR SYSTEMIC USE ➤ Terbinafine and griseofulvin are classified in D01B.	J2	SYSTEMIC AGENTS FOR FUNGAL INFECTIONS ➤ Terbinafine for systemic use is classified here. ➤ Griseofulvin is classified in D1A2.
❖	➤ All plain sulphonamides are classified in J01E. Sulfonamides,	J3	SYSTEMIC SULPHONAMIDES ➤ This group includes plain sulphonamides and

WHO (Substance based)

EphMRA (Product based)

combinations with other antibacterials (excl. trimethoprim) are classified in J01R.

sulphonamide/antibiotic combinations, excl trimethoprim/sulphonamides which are classified J1E.

❖		J3	SYSTEMIC SULPHONAMIDES
J04	ANTIMYCOBACTERIALS	J4	ANTIMYCOBACTERIALS
J04A	DRUGS FOR TREATMENT OF TUBERCULOSIS <ul style="list-style-type: none"> ➤ Rifampicin and rifamycin are classified here. ➤ Plain streptomycin is classified in J01G A. 	J4A	ANTITUBERCULAR PRODUCTS <ul style="list-style-type: none"> ➤ Rifampicin and rifamycin are classified here and in J1M. ➤ Streptomycin is classified here.
J04B	DRUGS FOR TREATMENT OF LEPROSY <ul style="list-style-type: none"> ➤ Thalidomide, also when used for leprosy, is classified L04A X. 	J4B	DRUGS FOR THE TREATMENT OF LEPROSY <ul style="list-style-type: none"> ➤ Thalidomide, when used for leprosy is classified here, otherwise it is classified in L4.
J05	ANTIVIRALS FOR SYSTEMIC USE	J5	ANTIVIRALS FOR SYSTEMIC USE
J05A	DIRECT ACTION ANTIVIRALS <ul style="list-style-type: none"> ➤ The combination of ribavirin and peginterferon is classified L03A. ➤ Antivirals acting against HIV are classified here in J05A E–J05A G depending on inhibition mechanism. 	J5B	ANTIVIRALS, EXCLUDING ANTI-HIV PRODUCTS <ul style="list-style-type: none"> ➤ The combination of ribavirin and peginterferon is classified here.
		+	
		J5C	HIV ANTIVIRALS <ul style="list-style-type: none"> ➤ HIV antivirals are classified here in J5C1 – J5C9 depending on inhibition mechanism.
J06	IMMUNE SERA AND IMMUNOGLOBULINS	J6	SERA AND GAMMA-GLOBULIN
J06A	IMMUNE SERA	J6A	ANTITOXIC SERA
J06B	IMMUNOGLOBULINS	J6C	POLYVALENT IMMUNO-GLOBULINS - INTRAVENOUS

WHO (Substance based)

EphMRA (Product based)

J6D	HOMOLOGOUS IMMUNOLOGICALLY ACTIVE GLOBULINS - INTRAVENOUS
+	
J6E	POLYVALENT IMMUNO-GLOBULINS - INTRAMUSCULAR
+	
J6F	POLYVALENT IMMUNO-GLOBULINS – COMBINATION MODULATION - MAINLY INTRAMUSCULAR
+	
J6G	SPECIFIC IMMUNOGLOBULINS - ANTIBACTERIAL
+	
J6H	SPECIFIC IMMUNOGLOBULINS - ANTIVIRAL
+	
J6J	OTHER SPECIFIC IMMUNOGLOBULINS

J07 VACCINES

J07A BACTERIAL VACCINES

- Also includes combinations of bacterial vaccines.

+

J07B VIRAL VACCINES

- Also includes combinations of viral vaccines.

J07C BACTERIAL AND VIRAL VACCINES, COMBINED

- Bacterial vaccines combinations and viral vaccines combination are classified J07A and J07B respectively.

J7 VACCINES

J7A PURE VACCINES

- All vaccines that act against a specific group of virus or bacteria are classified here. All combinations acting against more than one group of virus or bacteria are classified in J7B.

- Viral vaccines are classified in J7A if acting against a specific group of virus. Combinations are classified in J7B.

J7B COMBINATIONS OF VACCINES

- All combinations of bacterial and viral vaccines are classified here.

WHO (Substance based)

EphMRA (Product based)

J07X OTHER VACCINES

J7C ALL OTHER VACCINES

WHO (Substance based)

EphMRA (Product based)



➤ Parenteral imidazole formulations are classified in J01X D.

J8

OTHER ANTI-INFECTIVES

➤ Parenteral imidazole formulations are classified here in J8B.

WHO (Substance based)

EphMRA (Product based)

L	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01	ANTINEOPLASTIC AGENTS
L01A	ALKYLATING AGENTS ➤ Altretamine is classified in L01X.
L01B	ANTIMETABOLITES ➤ Methotrexate is classified in L01B and L04A.
L01C	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS ➤ Irinotecan and topotecan are classified in L01X X.
L01D	CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES ➤ Gemtuzumab ozogamicin is classified in L01X.
L01X	OTHER ANTINEOPLASTIC AGENTS ➤ Altretamine is classified here. ➤ Aminolevulinic acid is classified here. ➤ Alitretinoin is classified in D11A . ➤ Irinotecan and topotecan are classified here in L01X X. ➤ Ibritumomab tiuxetan, tositumomab and iodine (131I) tositumomab are classified in V10X.
L01X A	Platinum compounds
L01X B	Methylhydrazines
L01X C	Monoclonal Antibodies

L	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L1	CYTOSTATICS
L1A	ALKYLATING AGENTS ➤ Altretamine is classified here.
L1B	ANTIMETABOLITES ➤ Methotrexate is classified in D5B, M1C and L01B.
L1C	VINCA ALKALOIDS AND OTHER PLANT PRODUCTS ➤ Irinotecan and topotecan are classified here.
L1D	CYTOSTATIC ANTINEOPLASTICS ➤ Gemtuzumab ozogamicin is classified here.
L1X	ALL OTHER ANTINEOPLASTICS ➤ Altretamine is classified in L1A. ➤ Aminolevulinic acid is classified here and in D5X. ➤ Irinotecan and topotecan are classified in L1C. ➤ Ibritumomab tiuxetan, tositumomab and iodine (131I) tositumomab are classified here.
L1X2	Platinum compounds
L1X9	All other antineoplastics
L1X3	Antineoplastic Monoclonal Antibodies

WHO (Substance based)

EphMRA (Product based)

	➤ Gemtuzumab ozogamicin is classified here.		➤ Gemtuzumab ozogamicin is classified in L1D.
L01X D	Agents used in photodynamic therapy	L1X9	All other antineoplastics
L01X E	Protein kinase inhibitors	L1X4	Antineoplastic protein kinase inhibitors
	➤ Ruxolitinib is classified here.		➤ Ruxolitinib is classified in B6C.
L01X X	Other antineoplastic agents	L1X1	Adjuvants preparations for cancer therapy
	➤ Sipuleucel-T is classified in L03X A.	+	➤ Alitretinoin is classified here when indicated to treat cutaneous lesions in Kaposi's sarcoma and in D5X when indicated for the treatment of eczema.
	➤ Aflibercept is classified in S01L.	L1X9	All other antineoplastics
			➤ Sipuleucel-T is classified here.
			➤ Aflibercept is classified here and in S1P.

L02 ENDOCRINE THERAPY

L02A HORMONES AND RELATED AGENTS

L02A A Estrogens

L02A B Progestogens

L02A E Gonadotrophin releasing hormone analogues

L02A X Other Hormones

L02B HORMONE ANTAGONISTS AND RELATED AGENTS

L02B A Anti-estrogens

➤ Fulvestrant is classified here.

L02B B Anti-androgens

L2 CYTOSTATIC HORMONE THERAPY

L2A CYTOSTATIC HORMONES

L2A1 Cytostatic oestrogens

L2A2 Cytostatic progestogens

L2A3 Cytostatic gonadotrophin releasing hormone analogues

L2A9 Other cytostatic hormones

L2B CYTOSTATIC HORMONE ANTAGONISTS

L2B1 Cytostatic anti-estrogens

➤ Fulvestrant is classified in L2B9.

L2B2 Cytostatic anti-androgens

WHO (Substance based)

EphMRA (Product based)

	<ul style="list-style-type: none">➤ All plain cyproterone preparations (and combinations of cyproterone and estrogen) regardless of indication are classified here.➤ Abiraterone is classified in L02B X.		<ul style="list-style-type: none">➤ Plain cyproterone preparations are classified here and in G3X depending on indication.➤ Abiraterone is classified here.
L02B G	Aromatase inhibitors	L2B3	Cytostatic aromatase inhibitors
L02B X	Other hormone antagonists and related agents	L2B9	Other cytostatic hormone antagonists
	<ul style="list-style-type: none">➤ Abiraterone is classified here.➤ Fulvestrant is classified in L02B A.		<ul style="list-style-type: none">➤ Abiraterone is classified in L2B2.➤ Fulvestrant is classified here.
L03 IMMUNOSTIMULANTS		L3 IMMUNOMODULATING AGENTS	
L03A	CYTOKINES AND IMMUNOMODULATORS	L3A	IMMUNOSTIMULATING AGENTS, EXCL. INTERFERONS
	<ul style="list-style-type: none">➤ Levamisole is classified in P02C E.		<ul style="list-style-type: none">➤ Levamisole, when indicated as immunostimulant, is classified here.
L03A A	Colony stimulating factors	L3A1	COLONY STIMULATING FACTORS
L03A C + L03A X	Interleukins + Other cytokines and immunomodulators	L3A9	All other immunostimulating agents excluding interferons
	<ul style="list-style-type: none">➤ Sipuleucel-T is classified here.		<ul style="list-style-type: none">➤ Sipuleucel-T is classified in L1X9.
L03A B	INTERFERONS	L3B	INTERFERONS
			<ul style="list-style-type: none">➤ Interferons indicated for viral hepatitis only are classified in J5B.
L04 IMMUNOSUPPRESSANTS		L4 IMMUNOSUPPRESSIVE AGENTS	
L04A	IMMUNOSUPPRESSANTS	+	These are split between L4B for anti-TNFs and L4X for other immunosuppressants.
	<ul style="list-style-type: none">➤ Alefacept is classified here.		

WHO (Substance based)

- Abatacept, anakinra, leflunomide and tocilizumab are classified here.
- Methotrexate is classified in L01B and L04A.
- Ustekinumab is classified here.
- Thalidomide is classified here.

EphMRA (Product based)

- Alefacept is classified in D5B.
- Abatacept, anakinra, leflunomide and tocilizumab are classified in M1C .
- Methotrexate is classified in D5B, M1C and L01B.
- Ustekinumab is classified in D5B.
- Thalidomide, when used for lepra is classified in J4B, otherwise it is classified here.



L4B

ANTI-TNF PRODUCTS



L4X

OTHER IMMUNOSUPPRESSANTS

WHO (Substance based)

EphMRA (Product based)

M	MUSCULO-SKELETAL SYSTEM	M	MUSCULO-SKELETAL SYSTEM
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	M1	ANTIINFLAMMATORY AND ANTI-RHEUMATIC PRODUCTS
M01A	ANTIINFLAMMATORY and ANTIRHEUMATIC PRODUCTS, NON STEROIDS <ul style="list-style-type: none">➤ This group comprises antiinflammatory preparations for systemic use, regardless of strength.➤ Mefenamic acid is classified here.➤ Ketorolac is classified here.➤ Chondroitin, Diacerein and Glucosamine are classified here.	M1A	ANTI-RHEUMATIC, NON STEROIDAL <ul style="list-style-type: none">➤ Anti-inflammatory analgesics used for both musculo-skeletal conditions and analgesia are classified in M1A. Those that are indicated mainly for general pains are in N2B.➤ Mefenamic acid is classified in N2B.➤ Ketorolac is classified in N2B.➤ Chondroitin, Diacerein and Glucosamine are classified in M5X.
M01B	ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION		
M01B A	Antiinflammatory/antirheumatic agents in combination with corticosteroids	M1B	ANTI-RHEUMATIC CORTICOSTEROID COMBINATIONS
M01C	SPECIFIC ANTIRHEUMATIC AGENTS <ul style="list-style-type: none">➤ Chloroquine is classified in P01B.➤ Anakinra, abatacept, leflunomide and tocilizumab are classified in L04A.➤ Methotrexate is classified in L01B and L04A.	M1C	SPECIFIC ANTI-RHEUMATIC AGENTS <ul style="list-style-type: none">➤ Chloroquine is classified here and in P1D.➤ Anakinra, abatacept, leflunomide and tocilizumab are classified here.➤ Methotrexate is classified in D5B, M1C and L01B.
M02	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	M2	TOPICAL ANTI-RHEUMATICS AND ANALGESICS
M02A	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN <ul style="list-style-type: none">➤ Bendazac is classified here.➤ Bufexamac is classified here.	M2A	TOPICAL ANTI-RHEUMATICS AND ANALGESICS <ul style="list-style-type: none">➤ Bendazac is classified in D3A.➤ Bufexamac is also classified in D4A.

WHO (Substance based)

- Chymotrypsin is classified in B06A A when used as haematological enzymes.

EphMRA (Product based)

- Nimesulide in throat preparations is also classified in R2A.
- Chymotrypsin is classified here or in A9A, C5B, D3A and V3H depending on indications.

M03	MUSCLE RELAXANTS	M3	MUSCLE RELAXANTS
M03A	MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS ➤ Dantrolene is classified in M03C.	M3A	MUSCLE RELAXANTS, PERIPHERALLY ACTING ➤ Dantrolene is classified here.
M03B	MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS	M3B	MUSCLE RELAXANTS, CENTRALLY ACTING
M03C	MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS ➤ Dantrolene is classified here.	❖	➤ Dantrolene is classified in M3A.
M04	ANTI-GOUT PREPARATIONS	M4	ANTI-GOUT PREPARATIONS
M04A	ANTI-GOUT PREPARATIONS	M4A	ANTI-GOUT PREPARATIONS
M5	DRUGS FOR TREATMENT OF BONE DISEASES	M5	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M05B	DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION ➤ Eptotermin alfa is classified here. ➤ Dibotermin alfa is classified here.	M5B	BONE CALCIUM REGULATORS ➤ Eptotermin alfa is classified in M5X. ➤ Dibotermin alfa is classified in M5X.
M09	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	❖	
M09A A	Quinine and DERIVATES		
+			
M09A X	Other drugs for disorders of the Musculo-skeletal system	Included in	ALL OTHER MUSCULOSKELETAL PRODUCTS

WHO (Substance based)

- Eptotermin alfa is classified in M05B.
- Dibotermin alfa is classified in M05B

M09A B Enzymes

- Bromelains is classified in B06A A.
- Chymotrypsin and trypsin are classified in B06A A when used as haematological enzymes.

EphMRA (Product based)

- M5X
- Eptotermin alfa is classified here.
 - Dibotermin alfa is classified here.

V3H ANTI INFLAMMATORY ENZYMES

- Bromelains is classified here or, in A9A and D3A depending on indications.
- Chymotrypsin is classified here or in A9A, C5B, D3A and M2A depending on indications.

WHO (Substance based)

EphMRA (Product based)

N NERVOUS SYSTEM

N01 ANESTHETICS

N01A ANESTHETICS, GENERAL

- Droperidol is classified in N5A.

N01B ANESTHETICS, LOCAL

- Capsicum for neuropathic pain is classified here, otherwise it is in M02A.

N02 ANALGESICS



- All antiinflammatory products are classified in M01A, regardless of strength.
- Analgesic/cold preparations are classified here intended for use as pain relief.
- Analgesics indicated for dysmenorrhea are classified here.

N02A OPIOIDS



- This classification is based solely on substances, not on legal status.
- Dihydrocodeine is classified here.
- Droperidol is classified in N5A.

N02B OTHER ANALGESICS AND ANTIPYRETICS



- Nabiximols (cannabidiol and tetrahydrocannabinol) is classified here.

N CENTRAL NERVOUS SYSTEM

N1 ANAESTHETICS

N1A ANAESTHETICS, GENERAL

- Phenoperidine and anileridine are classified in N2A.
- Droperidol is classified here or in N2A or N5A.

N1B ANAESTHETIC LOCAL

- Topical capsicum is classified in M2A or, when used for neuropathic pain, in N7X.

N2 ANALGESICS

- Anti-inflammatory analgesics used for both musculo-skeletal conditions and analgesia are classified in M01A. Those that are indicated mainly for general pains are in N2B.
- Analgesic/cold preparations are classified in R5A.
- Products specifically indicated for dysmenorrhea are classified in G2X1.

N2A NARCOTICS

- Includes all analgesics classified as narcotics in accordance with the legal definition of narcotic analgesics in each country.
- Dihydrocodeine is classified in N2B.
- Droperidol is classified here, or in N1A or N5A.

N2B NON-NARCOTICS AND ANTI-PYRETICS

- Nabiximols (cannabidiol and tetrahydrocannabinol), used for refractory spasticity, is classified in N7X.

WHO (Substance based)

EphMRA (Product based)

- N02C** **ANTIMIGRAINE PREPARATIONS**
- Dihydroergotamine which is also used in the treatment of hypotension, is classified in this group.
 - Pizotifen is classified here.
 - Lisuride (low dose) is classified here and in G02C (high dose).
 - Flumedroxone is classified here.

- N2C** **ANTI MIGRAINE PREPARATIONS**
- Dihydroergotamine is classified here and also in C1C1.
 - Pizotifen is classified here and in A15.
 - Lisuride is classified in N4A.
 - Flumedroxone is classified in G3D.

N03 **ANTIEPILEPTICS**

N3 **ANTI-EPILEPTICS**

N03A **ANTIEPILEPTICS**

N3A **ANTI-EPILEPTICS**

N04 **ANTI-PARKINSON DRUGS**

N4 **ANTI-PARKINSON DRUGS**

- Lisuride is classified in N02C and in G02C.

- Lisuride is classified here.

N05 **PSYCHOLEPTICS**

N5 **PSYCHOLEPTICS**

The group is divided into therapeutic subgroups:

The group is divided into therapeutic subgroups:

N05A – Antipsychotics

N5A – Antipsychotics

➤ N05B – Anxiolytics

➤ N5B – Hypnotic/Sedatives

➤ N05C – Hypnotics and sedatives

➤ N5C – Tranquilizers

N05A **ANTIPSYCHOTICS**

N5A **ANTIPSYCHOTICS**

- Lithium is classified here.
- Droperidol is classified here.

- Lithium is classified in N6A.
- Droperidol is classified here, or in N1A or N2A.

N05B **ANXIOLYTICS**

N5C **TRANQUILLISERS**

- Mebutamate is classified here.
- Mefenoxalone is classified here.

- Mebutamate is classified in C2A.
- Metenoxalone is classified in M3B.

WHO (Substance based)

EphMRA (Product based)

N05C	HYPNOTICS AND SEDATIVES ➤ Melatonin is classified here.	N5B	HYPNOTICS / SEDATIVES ➤ Melatonin (plain) indicated for sleep rhythm disturbances is classified in H4X. Prolonged-release melatonin indicated for primary insomnia is classified here.
N06	PSYCHOANALEPTICS	N6	PSYCHOANALEPTICS EXCL. ANTI-OBESITY PREPARATIONS
N06A	ANTIDEPRESSANTS ➤ Lithium is classified in N05A. ➤ Ademetionine is in A16A. ➤ Bupropion is classified here.	N6A	ANTI-DEPRESSANTS AND MOOD STABILISERS ➤ Lithium is classified here. ➤ Ademetionine is classified here. ➤ Bupropion is classified here and in N7B.
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS ➤ Dexamfetamine and metamfetamine are classified here. ➤ Caffeine is classified here. ➤ Citicoline is classified here. ➤ Atomoxetine is classified here.	N6B	PSYCHOSTIMULANTS ➤ Dexamfetamine and metamfetamine are classified here and in A8. ➤ Plain caffeine is classified in C1C1. ➤ Citicoline is classified in C4A. + ➤ Atomoxetine is classified in N7X.
		N6D	NOOTROPICS ➤ Citicoline is classified in C4A. +
		N6E	NEUROTONICS AND OTHER MISCELLANEOUS PRODUCTS
N06C	PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION	N6C	PSYCHOLEPTIC-PSYCHOANALEPTIC COMBINATIONS
N06D	ANTI-DEMENTIA DRUGS	N7D	ANTI-ALZHEIMER PRODUCTS

WHO (Substance based)

EphMRA (Product based)

N07 ➡	OTHER NERVOUS SYSTEM DRUG	N7	OTHER CNS DRUGS
N07A	PARASYMPATHOMIMETICS <ul style="list-style-type: none">➤ Nalorphine, naltrexone, naloxone and flumazenil are classified in V03A.➤ Cevimeline is classified here.	❖ Included in N7X	OTHER CNS DRUGS <ul style="list-style-type: none">➤ Nalorphine, naltrexone, naloxone and flumazenil are classified in N7X.➤ Cevimeline is classified in A01A.
N07B	DRUGS USED IN ADDICTIVE DISORDERS		
N07B A	Drugs used in nicotine dependence <ul style="list-style-type: none">➤ Bupropion is classified in N6A.	N7B	ANTISMOKING PRODUCTS <ul style="list-style-type: none">➤ Bupropion is classified here and in N6A (antidepressant).
N07B B	Drugs used in alcohol dependence	N7E	DRUGS USED IN ALCOHOL DEPENDENCE
N07B C	Drugs used in opioid dependence	N7F	DRUGS USED IN OPIOID DEPENDENCE
N07C	ANTIVERTIGO PREPARATIONS	N7C	ANTIVERTIGO PREPARATIONS
N07X	OTHER NERVOUS SYSTEM DRUGS <ul style="list-style-type: none">➤ Sugammadex is classified in V03A B here.➤ Topical capsicum, when used for neuropathic pain, is classified in N01B.➤ Nabiximols (cannabidiol and tetrahydrocannabinol) is classified in N02B.	N7X	<i>ALL OTHER CNS DRUGS</i> <ul style="list-style-type: none">➤ Sugammadex is classified here.➤ Topical capsicum, when used for neuropathic pain, is classified here.➤ Nabiximols (cannabidiol and tetrahydrocannabinol) is classified here.

WHO (Substance based)

EphMRA (Product based)

P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS

This group is subdivided according to types of parasites

P01 ANTIPROTOZOALS



P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES

- Systemic metronidazole is classified here and in J01X D.
- Clioquinol, chlorquinaldol, tilbroquinol and glycobiarsol are classified here.

P01B ANTI-MALARIALS

- Chloroquine and hydroxychloroquine are classified here.

P01C AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS



P02 ANTHELMINTICS



The anthelmintics are subdivided according to the main type of worms (i.e. trematodes, nematodes and cestodes) causing the infections.

- Levamisole is classified here.

P PARASITOLOGY

P1 ANTI-PARASITIC PRODUCTS



P1A AMOEBICIDES

- Nitroimidazole derivatives are classified either in G1A or J8B.
- Clioquinol, chlorquinaldol, tribroquinol and glycobiarsol are classified in A7A.

P1D ANTI-MALARIALS

- Chloroquine and hydroxychloroquine are classified here and in M1C.

P1G OTHER ANTI-PARASITIC AGENTS

P1C SCHISTOSOMICIDES



+

P1B ANTHELMINTICS, EXCL. SCHISTOSOMICIDES

- Levamisole is classified here in L3A.

WHO (Substance based)

EphMRA (Product based)

P03 **ECTOPARASITICIDES, INCL. SCABICIDES,
INSECTISIDES AND REPELLENTS**

P3 **ECTOPARASITICIDES, INCL. SCABICIDES, INSECTISIDES
AND REPELLENTS**

P03A ECTOPARASITICIDES, INCL. SCABICIDES

P3A ECTOPARASITICIDES, incl. SCABICIDES

P03B INSECTICIDES AND REPELLENTS
➤ Dimethylphthalate is classified here.

P3B INSECTICIDES AND REPELLENTS
➤ Dimethylphthalate is classified in D4A.

WHO (Substance based)

EphMRA (Product based)

R	RESPIRATORY SYSTEM
R01	NASAL PREPARATIONS
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01B	NASAL DECONGESTANTS FOR SYSTEMIC USE
R02	THROAT PREPARATIONS
R02A	THROAT PREPARATIONS
	➤ Preparations for the treatment of throat infections (lozenges for common cold condition) are classified here.
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
	This group is harmonized on the second level.
	➤ Alfa 1 antitrypsin (alpha-1-proteinase inhibitor) is classified in B02A.
	➤ Azelastine is classified in R06A.
	➤ Ketotifen is classified in R06A.
	➤ Terfenadine is classified in R06A.

R	RESPIRATORY SYSTEM
R1	NASAL PREPARATIONS
R01A	TOPICAL NASAL PREPARATIONS
R1B	SYSTEMIC NASAL PREPARATIONS
R2	THROAT PREPARATIONS
R2A	THROAT PREPARATIONS
	➤ Products indicated for both the posterior part of the mouth and throat infections are classified in R2A or A1A depending on the main indication.
	➤ Nimesulide in throat preparations is also here.
R3	ANTI-ASTHMA AND COPD PRODUCTS
	➤ Alpha-1-proteinase inhibitor (alfa 1 antitrypsin) is classified here.
	➤ Azelastine is classified here.
	➤ Ketotifen is classified here.
	➤ Terfenadine (Japan only) is classified here, in all other countries in R6A.



R4 CHEST RUBS AND OTHER INHALANTS

WHO (Substance based)

EphMRA (Product based)

R05	COUGH AND COLD PREPARATIONS	R5	COUGH AND COLD PREPARATIONS
➡	<ul style="list-style-type: none">➤ Cold preparations with therapeutic levels of antiinfectives should be classified in ATC group J – Antiinfectives for systemic use.➤ Cold preparations with therapeutic levels of analgesics/antiinflammatory agents should be classified in the respective N02/M01 groups.		<ul style="list-style-type: none">➤ COUGH/COLD PREPARATIONS WITH ANTI-INFECTIVES (R5B)➤ COLD PREPARATIONS WITHOUT ANTI-INFECTIVES (R5A)
R05C	EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS	R5C	EXPECTORANTS
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS	R5D	ANTITUSSIVES
	<ul style="list-style-type: none">➤ Cough suppressants with expectorants are in R05F.		<ul style="list-style-type: none">➤ Cough suppressants combination preparations are here in R5D2.
+			
R05F	COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS	R5F	OTHER COUGH AND COLD PREPARATIONS
			<ul style="list-style-type: none">➤ This group includes combinations without clearly expectorating or antitussive effect, expectorant teas and lozenges / medical sweets for cough.
R05X	OTHER COLD PREPARATIONS	❖	
R06	ANTIHISTAMINES FOR SYSTEMIC USE	R6	SYSTEMIC ANTIHISTAMINES
R06A	ANTIHISTAMINES FOR SYSTEMIC USE	R6A	SYSTEMIC ANTIHISTAMINES
	<ul style="list-style-type: none">➤ Antihistamines for systemic use are classified here.➤ Cyproheptadine is classified here.➤ Thiethylperazine is classified here.➤ Azelastine and ketotifen are classified here.		<ul style="list-style-type: none">➤ Antihistamines used in motion sickness are classified in A4A.➤ Cyproheptadine is also classified in A15.➤ Thiethylperazine is classified in A4A.➤ Azelastine and ketotifen are classified in R3C.

WHO (Substance based)

EphMRA (Product based)

R07	OTHER RESPIRATORY SYSTEM PRODUCTS
R07A	OTHER RESPIRATORY SYSTEM PRODUCTS
R07A A	LUNG SURFACTANTS
R07A B	RESPIRATORY STIMULANTS
R07A X	OTHER RESPIRATORY SYSTEM PRODUCTS

R7	OTHER RESPIRATORY SYSTEM PRODUCTS
R7C	LUNG SURFACTANTS
R7A	RESPIRATORY STIMULANTS
R7X	ALL OTHER RESPIRATORY SYSTEM PRODUCTS

WHO (Substance based)

EphMRA (Product based)

S	SENSORY ORGANS	S	SENSORY ORGANS
S01	OPHTHALMOLOGICALS	S1	OPHTHALMOLOGICALS
S01A	ANTIINFECTIVES	S1A	OPHTHALMOLOGICAL ANTI-INFECTIVES
S01A D	Antivirals	+	
		S1D	OPHTHALMOLOGICAL ANTIVIRAL AGENTS
S01B	ANTIINFLAMMATORY AGENTS	S1B	OPHTHALMOLOGICAL CORTICOSTEROIDS
S01B C	Antiinflammatory agents, non-steroids	+	
		S1R	OPHTHALMIC NONSTEROIDAL ANTIINFLAMMATORIES
S01C	ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION	S1C	OPHTHALMOLOGICAL ANTI-INFLAMMATORY/ANTIINFECTIVE COMBINATIONS
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS	S1E	MIOTICS AND ANTIGLAUCOMA PREPARATIONS
S01F	MYDRIATICS AND CYCLOPLEGICS	S1F	MYDRIATICS AND CYCLOPLEGICS
S01G	DECONGESTANTS AND ANTIALLERGICS	S1G	OCULAR ANTI-ALLERGICS, DECONGESTANTS, ANTISEPTICS
S01H	LOCAL ANESTHETICS	S1H	OPHTHALMOLOGICAL LOCAL ANESTHETICS
S01J	DIAGNOSTIC AGENTS	S1T	OPHTHALMOLOGICAL DIAGNOSTIC AGENTS
S01K	SURGICAL AIDS	S1S	OPHTHALMOLOGICAL SURGICAL AIDS
S1L	ANTINEOVASCULARISATION AGENTS ➤ Aflibercept is classified here.	S1P	OCULAR ANTINEOVASCULARISATION PRODUCTS ➤ Aflibercept is classified here and in L1X.

WHO (Substance based)**EphMRA (Product based)**

❖		S1K	ARTIFICIAL TEARS AND OCULAR LUBRICANTS
❖		S1L	PREPARATIONS FOR USE WITH CONTACT LENSES
❖		S1M	EYE TONICS and EYE VITAMINS
❖		S1N	PREPARATIONS TO PREVENT CATARACT AND ANTICATARACTOGENICS
S01X	OTHER OPHTHALMOLOGICALS	S1X	OTHER OPHTHALMOLOGICALS
S02	OTOLOGICALS	S2	OTOLOGICALS
S02A	ANTIINFECTIVES	S2A	OTIC ANTI-INFECTIVES
S02B	CORTICOSTEROIDS	S2B	OTIC CORTICOSTEROIDS
S02C	CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION	S2C	OTIC CORTICOSTEROID/ANTIINFECTIVE COMBINATIONS
S02D	OTHER OTOLOGICALS	S2D	OTHER OTOLOGICALS
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS	S3	OPHTHALMOLOGICAL/OTOLOGICAL COMBINATIONS
S03A	ANTIINFECTIVES	S3A	EYE/EAR ANTI-INFECTIVES
S03B	CORTICOSTEROIDS	S3B	EYE/EAR CORTICOSTEROIDS
S03C	CORTICOSTEROIDS AND ANTIINFECTIVES IN COMB.	S3C	EYE/EAR CORTICOSTEROID/ANTI-INFECTIVE COMBI.

WHO (Substance based)

EphMRA (Product based)

S03D OTHER OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS

S3D OTHER EYE/EAR COMBINATIONS

WHO (Substance based)

EphMRA (Product based)

V	VARIOUS	V	VARIOUS
V01	ALLERGENS	V1	ALLERGENS
V01A	ALLERGENS	V1A	ALLERGENS
V03	ALL OTHER THERAPEUTIC PRODUCTS	V3	ALL OTHER THERAPEUTIC PRODUCTS
V03A	ALL OTHER THERAPEUTIC PRODUCTS	V3A	❖
V03A B	ANTIDOTES ➤ Zinc acetate is classified in A16A. ➤ Sugammadex is classified here. ➤ Plain phentolamine as an antidote is classified here.	V3E	ANTIDOTES ➤ Zinc acetate is classified here when indicated for Wilson's disease. ➤ Sugammadex is classified in N7X. ➤ Phentolamine for erectile dysfunction is in G4E. ➤ Phentolamine when used as an antidote is classified in V3X.
V03A C	IRON CHELATING AGENTS	V3F	IRON-CHELATING AGENTS
V03A E	DRUGS FOR THE TREATMENT OF HYPERKALEMIA AND HYPERPHOSPHATEMIA	V3G	HYPERKALAEMIA/HYPERPHOSPHATEMIA PRODUCTS
V03A F	DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT	V3D	DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT
V03A G – V03A Z	➤ Nalfurafine is classified in V03A X. ➤ Phentolamine when used as an antidote/reversal agent is classified in V03A B. ➤ Trypsin is classified in B06A A when used as haematological enzymes.	V3X	ALL OTHER THERAPEUTIC PRODUCTS ➤ Nalfurafine is classified in D4A. ➤ Phentolamine when used as an antidote is classified here. ➤ Trypsin is classified here or in A9A and V3H depending on indications.

WHO (Substance based)

EphMRA (Product based)

V04 DIAGNOSTIC AGENTS



T

DIAGNOSTIC AGENTS

WHO (Substance based)

EphMRA (Product based)

V04B	URINE TESTS	T2C	PREGNANCY AND OVULATION TESTS
		T2D1	Diabetes tests, urine
		T2X1	All other diagnostic tests, urine
V04C	OTHER DIAGNOSTIC AGENTS	T2X2 +	All other diagnostic tests, blood
		T2X9	All other diagnostic tests
V04C A	Tests for diabetes	T2D2 +	Diabetes tests, blood
		T2D9	Diabetes tests, other
❖		T3	DIAGNOSTIC EQUIPMENT AND ACCESSORIES
V06	GENERAL NUTRIENTS	V6	DIETETIC AGENTS
V06A	DIET FORMULATIONS FOR TREATMENT OF OBESITY	V6A	SLIMMING PREPARATIONS
V06B	PROTEIN SUPPLEMENTS	V6B	PROTEIN SUPPLEMENTS
V06C	INFANT FORMULAS	V6C	INFANT FORMULAS
V06D	OTHER NUTRIENTS	V6D	OTHER NUTRIENTS
V07	ALL OTHER NON-THERAPEUTIC PRODUCTS	V7	ALL OTHER NON-THERAPEUTIC PRODUCTS
V07A	ALL OTHER NON-THERAPEUTIC PRODUCTS	V7A	ALL OTHER NON-THERAPEUTIC PRODUCTS
V08	CONTRAST MEDIA	❖	Classified in group T
V08A	X-RAY CONTRAST MEDIA, IODINATED	T1A +	LOW OSMOLAR ANGIO-UROGRAPHY

WHO (Substance based)

EphMRA (Product based)

		T1B +	IONIC ANGIO-UROGRAPHY
		T1D	CHOLECYSTOGRAPHY AND CHOLANGIOGRAPHY
V08B	X.RAY CONTRAST MEDIA, NON-IODINATED	T1C	GASTROENTEROGRAPHY
V08C	MAGNETIC RESONANCE IMAGING CONTRAST MEDIA	T1E	MRI AGENTS
V08D	ULTRASOUND CONTRAST MEDIA	❖	
		T1F	ULTRASOUND AGENTS
		T1X	OTHER IMAGING AGENTS
<hr/>			
V09	DIAGNOSTIC RADIOPHARMACEUTICALS	❖	Classified in group T
		T1G	RADIODIAGNOSTIC AGENTS
<hr/>			
V10	THERAPEUTIC RADIOPHARMACEUTICALS	V3C	RADIOPHARMACEUTICALS
	➤ Ibritumomab tiuxetan, tositumomab and iodine (131I) tositumomab are classified here.		➤ Ibritumomab tiuxetan, tositumomab and iodine (131I) tositumomab are classified in L1X.
<hr/>			
V20	SURGICAL DRESSINGS	❖	
